加载中
NASDAQHealthcareBiotechnology
最新数据
US$11.31
−US$0.03 · -0.26%
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
前收盘价
US$11.31
−US$0.03 · -0.26%
盘前
US$11.28
−US$0.03 · -0.27%
10月8日 7:43 ET
盘中时间采用ET。市场数据可能有所延迟。
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
日内区间
当前US$11.31
52周区间
当前US$11.31
盘中时间采用ET。市场数据可能有所延迟。
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
日内区间
当前US$11.31
52周区间
当前US$11.31
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 100万 USD | 760万 USD |
| 销货成本 | — | — | — | 10万 USD | 20万 USD |
| 毛利 | — | — | — | 90万 USD | 740万 USD |
| 研究与开发 | 1602.2万 USD | 1909.6万 USD | 2400.7万 USD | 3026.8万 USD | 2137.4万 USD |
| 销售、一般及管理费用 | 1225.2万 USD | 1241.7万 USD | 1386.2万 USD | 1258.2万 USD | 1132万 USD |
| 营业费用 | 2827.4万 USD | 3151.3万 USD | 3786.9万 USD | 4285万 USD | 3269.4万 USD |
| 利息收入 | 141.1万 USD | 63.2万 USD | 52.5万 USD | 31.7万 USD | 6000 USD |
| 折旧和摊销 | — | 3151.3万 USD | 3786.9万 USD | 45.7万 USD | 127.3万 USD |
| 营业利润 | −2827.4万 USD | −3151.3万 USD | −3786.9万 USD | −4195万 USD | −2529.4万 USD |
| 净利润 | −2686.3万 USD | −3088.1万 USD | −3734万 USD | −4130.1万 USD | −2069.9万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$35.00
上涨空间 209.46%报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI6730.15万0.65%100.75亿 USD0.35%US$150.23-0.44%
iShares Russell 2000 ETFIWM5962.28万0.08%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF2885.59万0.03%954亿 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO2134.7万0.15%142.49亿 USD0.24%US$355.37-1.43%
Vanguard Russell 2000 ETFVTWO1447.04万0.08%180亿 USD0.06%US$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA1189.23万0.05%216.99亿 USD0.03%US$32.61-1.47%
Vanguard Health Care ETFVHT800.66万0.04%220亿 USD0.09%US$315.31+0.78%
iShares Micro-Cap ETFIWC714.43万0.54%13.33亿 USD0.60%US$183.36-1.09%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
